Brainomix is an Oxford University spinout using artificial intelligence to improve diagnosis and treatment decisions in stroke and lung disease.
Brainomix’s mission
Founded on world-leading academic research, the company has developed software that helps clinicians interpret complex medical imaging more quickly and accurately, supporting faster treatment decisions and helping to improve patient outcomes.
The company’s technology is designed to address one of healthcare’s most significant challenges: ensuring that critical decisions can be made rapidly, particularly in time-sensitive conditions such as stroke. By applying advanced AI algorithms to medical images, Brainomix provides healthcare professionals with additional insights that can help identify patients who may benefit from treatment and support more informed clinical decision-making.
In the latest episode of Meet the Portfolio, CEO and Co-Founder Dr Michalis Papadakis discusses the origins of Brainomix, the clinical challenge that inspired its creation, and the journey from university spinout to international healthcare company.
The conversation explores the evolution of AI in healthcare, the opportunities and challenges involved in bringing academic research to market, and what it takes to build and scale a deeptech business within a highly regulated industry. Dr Papadakis also reflects on the importance of collaboration between researchers, clinicians and industry partners, as well as the factors that have helped Brainomix expand its reach across international healthcare systems.
As with many successful university spinouts, Brainomix’s story demonstrates how scientific innovation can move beyond the laboratory to deliver tangible benefits for patients, clinicians and healthcare providers. The company continues to operate at the intersection of artificial intelligence, medical imaging and healthcare, developing technologies designed to support faster diagnoses and more effective treatment pathways.
Watch the video to learn more about Brainomix’s story, its growth journey, and its experience as part of the Parkwalk portfolio.
To find out more about Brainomix, visit their website or our portfolio page here.